Arcus Biosciences, Inc.
RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimabā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$21.69
Price+5.04%
$1.04
1Y
Price
Market Cap
$2.184b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-245.4%
EBITDA Margin-297.0%
Net Profit Margin-366.7%
Free Cash Flow Margin-245.4%
EBITDA Margin-297.0%
Net Profit Margin-366.7%
Free Cash Flow MarginRevenue
$247m
-4.3%
1y CAGR+40.2%
3y CAGR+12.5%
5y CAGREarnings
-$353m
-24.7%
1y CAGR-10.6%
3y CAGR-158.9%
5y CAGREPS
-$3.29
-4.8%
1y CAGR+2.6%
3y CAGR-153.7%
5y CAGRBook Value
$631m
$1.139b
Assets$508m
Liabilities$99m
DebtDebt to Assets
8.7%
-0.3x
Debt to EBITDAFree Cash Flow
-$484m
-175.0%
1y CAGR-101.6%
3y CAGR-12.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company